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Brain µ-opioid receptors (MORs) stimulate high-fat (HF) feeding and have been
implicated in the distinct long term outcomes on body weight of bariatric surgery and
dieting. Whether alterations in fat appetite specifically following these disparate weight
loss interventions relate to changes in brain MOR signaling is unknown. To address
this issue, diet-induced obese male rats underwent either Roux-en-Y gastric bypass
(RYGB) or sham surgeries. Postoperatively, animals were placed on a two-choice diet
consisting of low-fat (LF) and HF food and sham-operated rats were further split into
ad libitum fed (Sham-LF/HF) and body weight-matched (Sham-BWM) to RYGB groups.
An additional set of sham-operated rats always only on a LF diet (Sham-LF) served as
lean controls, making four experimental groups in total. Corresponding to a stage of
weight loss maintenance for RYGB rats, two-bottle fat preference tests in conjunction
with small-animal positron emission tomography (PET) imaging studies with the selective
MOR radioligand [11C]carfentanil were performed. Brains were subsequently collected
and MOR protein levels in the hypothalamus, striatum, prefrontal cortex and orbitofrontal
cortex were analyzed by Western Blot. We found that only the RYGB group presented
with intervention-specific changes: having markedly suppressed intake and preference
for high concentration fat emulsions, a widespread reduction in [11C]carfentanil binding
potential (reflecting MOR availability) in various brain regions, and a downregulation of
striatal and prefrontal MOR protein levels compared to the remaining groups. These
findings suggest that the suppressed fat appetite caused by RYGB surgery is due to
reduced brain MOR signaling, which may contribute to sustained weight loss unlike the
case for dieting.
Keywords: bariatric surgery, caloric-restriction, fat appetite, Brain µ-opioid receptors, positron emission
tomography imaging
Hankir et al. RYGB Reduces Brain µ-opioid Receptors
INTRODUCTION
The current obesity pandemic is primarily a consequence of
the sudden widespread ease of access to palatable, energy-dense
foods (Swinburn et al., 2011). Overeating in the face of plenty
results from a complex interaction of emotional, cognitive and
hedonic pressures which outweigh homeostatic processes in place
to maintain stable body weight (Alsiö et al., 2012). A rich
heritage of pharmacological studies has provided a picture of
how opioidergic circuits interface with the brain systems that
orchestrate feeding behavior (Bodnar, 2013). In rodents, agonists
of the µ-opioid receptor (MOR) in particular have consistently
been demonstrated to stimulate food intake when administered
into various hypothalamic nuclei (Stanley et al., 1988), the central
nucleus of the amygdala (Gosnell, 1988), ventromedial prefrontal
and orbitofrontal cortices (Mena et al., 2011), and especially the
striatum (Bakshi and Kelley, 1993). Here, acute administration
of a selective MOR agonist into the nucleus accumbens potently
stimulates, whereas a MOR antagonist inhibits fat intake in
sated and fasted rats, respectively (Zhang et al., 1998). Moreover,
intracerebral administration of antisense oligonucleotides against
the MOR inhibits food intake and lowers body weight (Leventhal
et al., 1996) while chronic administration of an irreversible MOR
antagonist into the nucleus accumbens inhibits high-fat (HF) diet
intake and prevents weight gain in rats (Lenard et al., 2010).
These findings provide a rationale for the evaluation of MOR
antagonists in weight loss studies performed on obese patients
(Greenway et al., 2010; Ziauddeen et al., 2013).
Despite being by far the most efficacious treatment for
obesity, little is known about how bariatric surgery affects the
brain control of food intake to achieve sustained weight loss
(Manning et al., 2015). Recently, a human positron emission
tomography (PET) imaging study with the selective MOR
radioligand [11C]carfentanil revealed widespread changes in
brainMOR availability in obese subjects compared to lean, which
were completely normalized after bariatric surgery (Karlsson
et al., 2016). While a separate study reported modest changes
in brain MOR availability in obese subjects after dieting
(Burghardt et al., 2015), a direct comparison between these
differing means of weight loss under standardized conditions
has not been performed. This forms an important basis
for gaining a better understanding of the central molecular
underpinnings of successful long-term weight reduction unique
to bariatric surgery. Additionally, it remains unclear whether
alterations in brain MOR signaling following Roux-en-Y
gastric bypass (RYGB), the most frequently employed bariatric
surgical procedure, relates to the documented postoperative
suppression in fat appetite in human (Kenler et al., 1990; Olbers
et al., 2006; Thomas and Marcus, 2008) and animal (Zheng
et al., 2009; le Roux et al., 2011; Shin et al., 2011b; Hao et al.,
2016) studies. We therefore performed detailed fat intake and
preference measurements in conjunction with in vivo small-
animal [11C]carfentanil PET imaging studies in lean and diet-
induced obese rats in comparison with animals that experienced
identical weight loss from RYGB or chronic caloric-restriction.
We then analyzed MOR protein expression in various brain
regions by Western Blot.
MATERIALS AND METHODS
Animals
Sixteen male Wistar rats (RjHan:WI, outbred, Janvier, Le Genest-
Saint-Isle, France) were used for our studies. Food and water
were provided ad libitum unless otherwise stated. Animals were
initially group housed and maintained on a 12-h light/dark cycle
(lights on at 07:00 h) in facilities with an ambient temperature of
21–23◦C and 40–60% humidity. All experiments were approved
by the Institutional Animal Care and Use Committee at the
Universität Leipzig with permission of the local government
of Saxony (Regional Administrative Authority Leipzig, TVV
63/13, Germany). When indicated, diet induced obesity (DIO)
was induced in 9 week old rats (n = 12) initially weighing
approximately 350 g by feeding them for 5 weeks with a HF
diet, which provides 58% of total energy as fat, 25.5% as
carbohydrate, and 16.5% as protein (EF D12331, Ssniff GmbH,
Soest, Germany). A separate group of rats always maintained on
standard laboratory chow with 9% kcal derived from fat (RM1
diet; Ssniff GmbH, DE-59494, Germany) served as lean controls
(n= 4).
Abdominal Surgeries and Postoperative
Care
All abdominal surgical procedures were performed after an
overnight fast by a bariatric surgeon according to a previously
established protocol (Hankir et al., 2015; Seyfried et al., 2016).
Briefly, animals were anesthetized with 5% isoflurane in 2 l/min
oxygen and then maintained on 1.8–2.3% isoflurane in 0.5 l/min
oxygen. Following induction of anesthesia, the abdominal wall
was opened by a midline incision. For the RYGB procedure
(n = 4), the jejunum was transected 15 cm aboral to the pylorus
to create a 10 cm biliopancreatic limb. The proximal end was
anastomosed to the ileum approximately 25 cm oral from the
cecum, creating the common channel. The stomach was then
transected 3 mm aboral to the gastroesophageal junction. At the
proximal end, the gastric pouch (2–3% original stomach size) was
anastomosed in an end-to-side fashion to the distal end of the
small bowel forming the alimentary limb. At the distal end, the
gastric remnant was closed using continues sutures. For the sham
procedure (n = 12), the small bowel and the gastroesophageal
junction were mobilized, and a 1 cm long gastrostomy was
performed on the anterior wall of the stomach with subsequent
closure. For postoperative analgesia, carprofen (5mg/kg i.p.)
was administered intraoperatively and then daily for 1 week.
Postoperatively, all animals were singly-housed.
Postoperative Diet Regimens
Standard laboratory chow with 9% kcal derived from fat
(RM1 diet; Ssniff GmbH, DE-59494, Germany) mixed with
water (wet diet) was given to all animals for 48 h following
surgeries. Afterwards, the lean Sham-LF control group was
maintained on standard laboratory chow, whilst the remaining
DIO animals were postoperatively given a two-choice diet of
standard laboratory chow and HF diet with 58% kcal derived
from fat (EF D12331, Ssniff GmbH, DE-59494, Germany). DIO
sham-operated animals were then randomly allocated into an ad
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libitum fed group (Sham-LF/HF group; n = 4) or a chronically
food-restricted group body weight-matched to RYGB rats (Sham-
BWM group; n = 4). To achieve this, animals from the Sham-
BWM group were given approximately the same amount of HF
diet as that consumed daily by the RYGB group in the early light
phase, but the amount of LF diet was adjusted accordingly. Body
weight and food intake were recorded daily for 12 weeks. This
time-point after surgery corresponds to a stage of weight loss
maintenance in our RYGB model (Hankir et al., 2015; Seyfried
et al., 2016).
Behavioral Protocol for Oral Fat Intake
During weeks 12–14 postoperatively, rats underwent 18-h
two-bottle preference tests in which consumption of 5%
concentration of an IntraLipid R© fat emulsion (Fresenius Kabi,
UK) was assessed. This concentration of fat emulsion was
chosen based on previous observations (le Roux et al., 2011;
and own unpublished data). After habituation with two water
bottles for 72-h, ad libitum fed animals lacking side preferences
had their food withdrawn and were then presented with two
other bottles: one that contained 150 ml of water and the
other 150 ml of 5% IntraLipid R© solution on randomized
sessions. Volumes ingested over 18 h were measured using an
automated feeding-drinking monitoring system (TSE Systems
GmbH, Bad Homburg, Germany). The preference ratio for
fat emulsion was calculated as the ratio (%) between the
volume ingested of fat emulsion and the total volume of fluid
ingested.
Synthesis of [11C]carfentanil
[11C]carfentanil was prepared according to a previously reported
procedure (Dannals et al., 1985) applying the “loop method”
(Wilson-Pérez et al., 2013). Specific activity as determined
by high-performance liquid chromatography was 5.8 · 105
MBq/nmol.
Small-Animal PET Imaging Protocol with
the Radioligand [11C]carfentanil
During weeks 15–17 postoperatively, animals underwent PET
scanning under ad libitum fed conditions (just prior to feeding
for the Sham-BWM group) using a dedicated small-animal
PET/MR system (nanoScan R©, Mediso Medical Imaging Systems,
Budapest, Hungary) as previously described (Nagy et al., 2013).
All PET scans were performed in the morning hours between 8
a.m. and 10 a.m. Rats were anaesthetized with 1.8% isoflurane
in 0.5 l/min 60% oxygen/40% air mixture (Gas Blender 100
Series, MCQ instruments, Rome, Italy) before receiving a
bolus intravenous injection of 41.6 ± 6.4 MBq [11C]carfentanil
via the lateral tail vein. Simultaneous to tracer injection, a
dynamic 35 min PET scan was initiated, during which animals
were maintained at 37◦C with a thermal bed system under
isoflurane anesthesia. As animals’ heads were too large to fit
into the MR coil for subsequent MR imaging, for anatomical
orientation a second static 15 min PET scan was performed
immediately afterwards following intravenous bolus injection
of approximately15 MBq [18F]- fluordeoxyglucose (FDG). The
list-mode data for the [11C]carfentanil scan were rebinned
into 28 frames (12 × 10, 6 × 30 s, 5 × 1 and 5 ×
5 min) and iteratively reconstructed with 3D-ordered subset
expectation maximization (OSEM), 4 iterations and 6 subsets
using an energy window of 400–600 keV, coincidence mode
of 1–5 and ring difference of 81. Cerebellum was selected
as a reference region as a previous study performed on rats
revealed minimal uptake of [11C]carfentanil in this brain region
following intravenous administration (Quelch et al., 2014).
[11C]carfentanil binding potential (BPND) was calculated using
the simplified reference tissue model (Lammertsma and Hume,
1996) for hypothalamus, thalamus, amygdala, striatum, cingulate
cortex, insular cortex, prefrontal cortex and orbitofrontal cortex,
again using the cerebellum as a reference region. This was
performed after automatic co-registration of the [18F]-FDG PET
images with a standard [18F]-FDG rat brain atlas using PMOD
(v.3.6, PMOD Technology, Zurich, Switzerland) software. The
final resolution of rendered PET images for analysis was
0.2 mm3.
Western Blot
At postoperative week 18, ad libitum fed rats were sacrificed
and brains rapidly removed. Hypothalamus, striatum, prefrontal
cortex and orbitofrontal cortex were carefully dissected and
frozen immediately in liquid nitrogen. Protein was extracted
from tissue (50mg) in radioimmunoprecipitation assay (RIPA)
buffer (40µl/mg) after homogenization and incubation at 4◦C for
1 h. Lysate was centrifuged for 15 min and supernatant collected.
Sample (10µg protein determined using a bicinchoninic acid
(BCA) protein assay kit (ThermoFisher Scientific, Darmstadt,
Germany)) was loaded into polyacrylamide gel, resolved
by electrophoresis (125V for 2 h) and transferred onto a
nitrocellulose membrane using a semi-dry method (75 mA
for 1 h). Membranes were blocked with 3% bovine serum
albumin (BSA) for 30min and after washing were incubated
overnight at 4◦C with rabbit anti-rat MOR monoclonal primary
antibody (AbCam, Cambridge, UK) diluted 1/1000 in 3 % BSA.
Membranes were then incubated for 1 h at room temperate
with goat anti-rabbit IgG secondary antibody conjugated to
horseradish peroxidase (Cell Signaling Technology, Leiden,
Netherlands) diluted 1/3000 in 3% BSA. Bands were visualized
using an enhanced chemiluminescence (ECL) kit (Biozym
Scientific GmbH, Oldendorf, Germany) and quantified using
the rolling method with GeneSnap software (v7.12, SynGene,
Cambridge, UK). As a loading control, membranes were
stripped with 0.2 N NaOH and β-actin was measured using
rabbit anti-rat β-actin monoclonal primary antibody (Sigma
Aldrich Chemie GmbH, Taufkirchen, Germany) diluted 1/500
in 3% BSA and then the same secondary antibody as for the
MOR.
Statistics
Data sets were analyzed for statistical significance using
GraphPad Prism software (v.7.02, GraphPad Software Inc.,
La Jolla, CA). One-way and two-way ANOVAs corrected for
multiple comparisons with Tukey’s post-hoc tests were used as
required.
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RESULTS
RYGB Surgery Reduces Body Weight, HF
Diet Intake, and Preference in Diet-Induced
Obese Male Rats
To confirm that our RYGB rat model recapitulates the human
phenotype observed after RYGB, body weight, food intake
and food preference were regularly measured postoperatively
compared to obese and lean control groups. With respect to body
weight (Figure 1A); preoperative values were similar between
Sham-LF/HF (418 ± 18.4 g), RYGB (451 ± 9.4 g), and Sham-
BWM (452 ± 4.4 g) groups but was significantly less (p < 0.01)
for the Sham-LF group (351 ± 3.4 g). From postoperative week
2, body weights started to significantly diverge (p < 0.0001)
between Sham-LF/HF and post-DIO weight loss groups (RYGB
and Sham-BWM) which continued for the duration of the 12
week recording period. Body weights of Sham-LF rats steadily
increased during this period so that they were similar to post-
DIO weight loss groups by week 12, but significantly less (p <
0.0001) than Sham-LF/HF rats.
Concerning total food consumption (Figure 1B), cumulative
energy intake over the 12 week recording period was considerably
lower (p < 0.01) for RYGB rats (1428 ± 71.5 kcal) compared
to Sham-LF/HF rats (1760 ± 39.7 kcal), but higher (p < 0.01)
compared to Sham-BWM rats (1074 ± 8.8 kcal). The similar
body weights despite different food intakes between RYGB and
Sham-BWM rats has previously been attributed to differences
in energy expenditure (Hankir et al., 2015). When focusing on
HF diet intake alone in groups given access (restricted or free)
to it (Figure 1B), consumption was markedly less (p < 0.01) for
RYGB (590 ± 105.5 kcal) and Sham-BWM rats (535 ± 3.5 kcal)
compared to Sham-LF/HF rats (996± 59.3 kcal). The amount of
HF diet given to Sham-BWM rats was ensured to be similar (p=
0.85) to that consumed by RYGB rats. Consequently, to cause and
sustain weight loss, Sham-BWM rats were given significantly less
(p< 0.05) LF diet (539± 5.3 kcal) than that consumed by RYGB
rats (839± 75.2 kcal).
With respect to dietary preference in groups with ad libitum
access to a choice diet (Figure 1C), RYGB rats showed an overall
reduced preference for HF diet relative to Sham-LF/HF rats over
the 12 week recording period [main effect of time F(11, 72) = 2.24;
p= 0.028,main effect of treatment F(1, 72) = 50.9; p< 0.0001, and
interaction F(11, 72) = 2.40; p = 0.013]. This difference started
at postoperative week 8 (64.6 ± 8.4% for Sham-LF/HF rats vs.
33.3 ± 7.7% for RYGB rats; p < 0.05) and was maintained until
postoperative week 12 (77.1± 7.1% for Sham-LF/HF rats vs. 50.0
± 7.9% for RYGB rats; p< 0.05).
RYGB Surgery Suppresses Appetite for
High Concentration Fat Emulsion
In order to study the effects of weight loss from RYGB and
chronic caloric-restriction on fat appetite in more detail, we
then performed two-bottle fat preference tests with a high
concentration (5%) IntraLipid R© emulsion on RYGB and Sham-
BWMgroups compared to obese (Sham-LF/HF) and lean (Sham-
LF) control groups. The RYGB group presented with a strikingly
lower (p < 0.01) intake of 5% IntraLipid R© relative to the
remaining groups (Figure 2A). Intake of 5% Intralipid R© over 18
h was 40 ± 4.6 ml for RYGB, 96 ± 1.5 ml for Sham-LF/HF, 99 ±
6.2 ml for Sham-BWM and 80 ± 9.7 ml for Sham-LF rats. When
calculated as preference over water (Figure 2B), the difference
between the RYGB group and the remaining groups became
more apparent (p < 0.0001). Preferences for high concentration
fat emulsion were 80 ± 2.8% for RYGB, 98 ± 0.5% for Sham-
LF/HF, 99 ± 0.3% for Sham-BWM, and 97 ± 0.7% for Sham-LF
rats.
RYGB Surgery Reduces Brain MOR
Availability
Having found differential effects of weight loss from RYGB
surgery and chronic caloric-restriction on fat appetite, we then
sought to determine the potential role of brain MORs for this
difference in feeding behavior. We therefore performed small-
animal PET imaging with the MOR radioligand [11C]carfentanil
FIGURE 1 | RYGB surgery reduces body weight, food intake and HF diet preference in diet-induced obese male rats. High-fat (HF) diet-induced obese rats
were split into 3 groups: Roux-en-Y gastric bypass-operated and then maintained on a choice diet (RYGB), sham-operated and then maintained on a choice diet
(Sham-LF/HF) and sham-operated and then body weight-matched to RYGB rats (Sham-BWM). A separate group of never obese sham-operated rats always
maintained on a LF diet (Sham-LF) was also added as lean controls. (A) Shows weekly body weights and (B) total cumulative energy intake over 12 weeks. In (A),
horizontal bar denotes significance between the Sham-LF/HF group and the remaining groups. In (B), lower bar segments represent energy in kcal consumed from
HF food and upper bar segments represent energy in kcal consumed from LF food. (C) Weekly HF diet preference was calculated by dividing the amount of HF diet
consumed with the total amount of diet (HF and LF) consumed and expressed as percentage (%). Data are presented as mean ± SEM. n = 4 per treatment group.
*p < 0.05, **p < 0.01 and ****p < 0.0001 vs. Sham-LF/HF, ##p < 0.05 vs. RYGB and ◦◦◦◦p < 0.0001 vs. Sham-LF for total energy intake; §§p < 0.01 vs.
Sham-LF/HF for HF food intake; &p < 0.05 vs. RYGB for LF food intake.
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FIGURE 2 | RYGB surgery suppresses intake and preference for high concentration lipid emulsions in diet-induced obese male rats. Two-bottle fat
preference tests were performed on Sham-LF/HF, RYGB, Sham-BWM and Sham-LF rats during postoperative weeks 12–14. Animals were presented with two
pre-measured bottles: one that contained water and the other HF emulsion containing 5% Intralipid®. (A) Volumes ingested were measured over the course of 18 h
and (B) fat preference was calculated by dividing the volume of 5% IntraLipid® consumed by that of the total volume of liquid (water and 5% Intralipid® ) consumed in
the session and expressed as percentage (%). Data are presented as mean ± SEM. n = 4 per treatment group. **p < 0.01, ***p < 0.001, ****p < 0.0001.
which provides a measure of brain MOR availability in vivo
(Burghardt et al., 2015; Karlsson et al., 2016). On the morning of
scans, Sham-LF/HF rats were significantly heavier (p < 0.0001)
compared to the remaining groups. Sham-LF/HF rats weighed
653 ± 3.3 g, RYGB rats weighed 508 ± 17.3 g, Sham-BWM rats
weighed 496 ± 14.1 g and Sham-LF rats weighed 501 ± 18.5 g.
After scanning, inspection of PET images revealed a widespread
reduction in [11C]carfentanil uptake in the brains of RYGB
rats compared to the remaining groups (Figure 3A). PET data
analysis for all subcortical (thalamus, hypothalamus, striatum,
and amygdala) and cortical (prefrontal cortex, orbitofrontal
cortex, cingulate cortex, and insular cortex) regions analyzed
are shown in Figures 3B,C, respectively. In subcortical regions,
[11C]carfentanil binding potential (BPND) was significantly lower
in RYGB rats relative to Sham-LF rats in the hypothalamus (p <
0.05), and amygdala (p < 0.01) and tended to be lower in the
striatum (p = 0.06). [11C]carfentanil BPND was also significantly
lower in RYGB animals relative to Sham-BWM animals in the
striatum (p < 0.05). In cortical regions, [11C]carfentanil BPND
was only significantly lower in RYGB rats relative to Sham-LF/HF
rats in the insular cortex (p< 0.05).
RYGB Surgery Reduces Striatal and
Prefrontal MOR Protein Expression
Considering the PET data showing widespread reductions in
brain MOR availability after RYGB, we next measured MOR
protein expression in brain regions involved in the opioidergic
control of feeding including the hypothalamus (Stanley et al.,
1988), striatum (Bakshi and Kelley, 1993; Zhang et al., 1998;
Lenard et al., 2010), orbitofrontal cortex (Mena et al., 2011),
and prefrontal cortex (Mena et al., 2011) in our experimental
groups by Western Blot. Immunoblots revealed a distinct 47
kDa band corresponding to the molecular weight of the MOR
(Figure 4). Analysis of band intensity normalized to β-actin
revealed lower values for the RYGB group relative to the
remaining groups (p < 0.05) in the striatum (Figure 4B),
and for the RYGB group relative to Sham-LF/HF (p < 0.05)
and Sham-LF (p < 0.05) groups in the prefrontal cortex
(Figure 4C).
DISCUSSION
Brain MORs are in prime position to be a molecular target
of RYGB due to their prominent role in regulating hedonic
feeding (Bodnar, 2013). In accordance with previous human
(Kenler et al., 1990; Olbers et al., 2006; Thomas and Marcus,
2008) and rodent (Zheng et al., 2009; le Roux et al., 2011; Shin
et al., 2011b; Hao et al., 2016) studies, we demonstrated that
RYGB reduces HF intake and preference using an established rat
model (Hankir et al., 2015; Seyfried et al., 2016). We found that
this was associated with widespread reductions in brain MOR
availability, particularly in the striatum. Furthermore, levels of
MOR protein in the striatum as well as in the prefrontal cortex
were downregulated after RYGB, which is consistent with the
known stimulatory effects of MOR agonism in these areas on fat
intake (Bakshi and Kelley, 1993; Mena et al., 2011). In contrast,
no changes in feeding behavior or brain MOR signaling were
observed in chronically food restricted Sham-BWM animals.
Reduced brain MOR signaling, therefore, may underlie the
postoperative suppression in HF food intake, contributing to
sustained weight loss caused by RYGB, unlike the case for chronic
food restriction.
Previous studies performed on rats support a key role for
nucleus accumbens MORs in the “liking” of palatable foods
(Richard et al., 2013). In this context, and in line with the findings
from the present study of reduced striatal MOR levels after
RYGB, patients and rats demonstrate measures of diminished
HF food liking postoperatively (Shin et al., 2011b; Ochner
et al., 2012). However, patients and rats also show the same
response following chronic caloric-restriction (Epstein et al.,
1989; Shin et al., 2011a). Considering that we did not find
alterations in striatal MORs in Sham-BWM rats, it appears
that changes in taste reactivity following weight loss caused by
chronic caloric-restriction may be dissociated from striatal MOR
signaling.
There is considerable overlap between the effects of RYGB and
reduced brain MOR signaling on brain function and behavior.
For instance, in human fMRI studies both RYGB and MOR
antagonist treatments decrease striatal blood oxygenation level
dependent signal when subjects are presented images of HF
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FIGURE 3 | Reduced brain MOR availability at a stage of weight loss maintenance after RYGB in diet-induced obese male rats. During postoperative
weeks 15–17, ad libitum fed Sham-LF/HF, RYGB, Sham-BWM and Sham-LF rats underwent small-animal PET imaging. Animals were anesthetized with isoflurane
and received the selective µ-opioid receptor (MOR) radioligand [11C]carfentanil intravenously at the onset of PET scanning for 35 min. (A) (Left) standard [18F]-FDG
rat brain PET atlas used to align PET images with brain masks superimposed and labeled. (Right) representative PET images of Sham-LF/HF, RYGB, Sham-BWM and
Sham-LF rat brains depicted as a standardized uptake value (SUV) ratio with cerebellum used as reference region based on frames 20–35 min. [11C]Carfentanil
binding potential ([11C]Carf. BPND) was calculated for individual (B) subcortical and (C) cortical regions of interest. Data are presented as mean ± SEM. n = 4 per
treatment group. *p < 0.05, **p < 0.01.
foods (Cambridge et al., 2013; Scholtz et al., 2014) and in
rat macronutrient studies, both RYGB and MOR antagonist
treatments suppress fat intake when carbohydrate, fat and
protein diets are presented simultaneously (Marks-Kaufman
and Kanarek, 1990; Wilson-Pérez et al., 2013). In addition,
patients who take opioids before RYGB tend to use higher
amounts after surgery (Raebel et al., 2013) and a recent
investigation revealed that male RYGB rats have markedly higher
morphine self-administration rates on a fixed ratio schedule of
reinforcement compared to obese, chronically caloric-restricted
and lean counterparts (Biegler et al., 2016). These latter
findings strongly support those of the present study of reduced
brain MOR signaling after RYGB, which may predispose to a
compensatory increase in opioid intake as is typically observed
with brain receptor downregulation/desensitization during drug
tolerance.
The reduced brain MOR availability following RYGB is body
weight independent and likely a consequence of altered gut-brain
communication. Circulating levels of the orexigenic stomach
hormone ghrelin have been previously reported to be decreased
in patients (Cummings et al., 2002) and rodents (Shin et al., 2010)
after RYGB. Considering that systemic administration of ghrelin
increases brain MOR mRNA expression in rats (Skibicka et al.,
2012), it is possible that the RYGB-mediated lowering in plasma
ghrelin contributes to reduced brain MOR levels postoperatively.
Profound changes in gut microbiota also take place after RYGB
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FIGURE 4 | Downregulation of striatal and prefrontal MOR protein levels at a stage of weight loss maintenance after RYGB in diet-induced obese male
rats. At postoperative week 18, ad libitum fed Sham-LF/HF, RYGB, Sham-BWM, and Sham-LF rats were sacrificed and brains were collected for Western Blot
analysis. Representative blots for MOR and β-actin in (A) hypothalamus, (B) striatum, (C) prefrontal cortex, and (D) orbitofrontal cortex for each group are presented.
In (A–D), MOR protein expression was quantified by normalizing band signal intensity to that of β-actin. Data are presented as mean ± SEM. n = 3/4 per treatment
group. *p < 0.05.
in humans and rodents (Furet et al., 2010; Liou et al., 2013; Shao
et al., 2016). Interestingly, secreted proteins from gut E. coli have
been found to influence brain opioidergic feeding circuits (Breton
et al., 2016) and may too underlie altered brain MOR signaling
after RYGB. Future mechanistic studies can address these issues
in more detail.
It was recently reported in human [11C]carfentanil PET
imaging studies that dieting exerts modest effects (Burghardt
et al., 2015) whereas bariatric surgery causes a widespread
increase in brain MOR availability in obese subjects (Karlsson
et al., 2016). With respect to the study of Burghardt et al.,
[11C]carfentanil BPND in various brain regions was not
significantly different between fasted obese individuals before
(BMI 38) and after (BMI 32) weight loss caused by 4
months of dieting. These findings are comparable with those
made in the present study with the Sham-LF/HF and Sham-
BWM animals. With respect to the study of Karlsson et al.
[11C]carfentanil BPND in thalamus, ventral striatum, dorsal
striatum, amygdala, insular cortex, and orbitofrontal cortex in
mildly fasted obese individuals was markedly increased 6 months
after bariatric surgery (BMI 31) relative to the preoperative
state (BMI 40). In contrast, here we report a reduction in
MOR availability in these brain regions postoperatively. This
finding was robust, attaining statistical significance despite the
low sample size. A possible explanation for the discrepant
findings between the present study and the study of Karlsson
et al. is that the timing of our scans corresponded to a late
postoperative stage of weight loss maintenance after RYGB,
whereas the subjects in the study of Karlsson et al. were
scanned at an early stage of active weight loss. We also
exclusively report findings from male rats after RYGB surgery,
whereas Karlsson et al. performed PET analysis on a mixed
population of female patients whom underwent two different
bariatric procedures (sleeve gastrectomy and RYGB). Indeed
the female sex hormones estrogen and progesterone both have
been shown to influence brain MOR expression (Hammer et al.,
1994).
A limitation of radioligand PET studies in general is that
binding potentials do not provide a strict measure of receptor
density. In the case for [11C]carfentanil, binding to the MOR
can be reduced as a result of competitive displacement by
endogenous opioids (Burghardt et al., 2015). However, we
found that in the striatum and prefrontal cortex at least,
RYGB downregulates MOR protein expression which may
underlie the reduced [11C]carfentanil binding in these regions.
Future cerebral microdialysis studies can reveal whether RYGB
influences brain opioid release in rats (Difeliceantonio et al.,
2012).
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In summary, we report that suppressed fat appetite at a stage
of weight loss maintenance after RYGB in male rats is associated
with reduced brain MOR availability. Bariatric surgery may
uniquely target various anatomically and molecularly discrete
brain feeding circuits (Haahr et al., 2015) at early and late time
points postoperatively (Mumphrey et al., 2016). Thus, treatments
which can mimic the dynamic neurochemical signature of
RYGB might effectively improve feeding behavior in the long-
term, causing and sustaining significant weight loss in obese
individuals.
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